Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Top companies in the Next Generation Sequencing Market
7 views
Skip to first unread message
MNM Reports
Dec 6, 2023, 12:34:38 AM12/6/23
to
The next-generation sequencing (NGS) market is anticipated to reach USD 27.0 billion by 2027, showing significant growth from USD 13.0 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 15.7% during the forecast period. Several factors contribute to this growth, including advancements in NGS technologies, an increasing incidence of cancer, a decreasing cost of genome sequencing, and improvements in regulatory and reimbursement scenarios for NGS-based diagnostic tests.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=546&utm_source=groups&utm_medium=K
The global NGS market is marked by high competitiveness, with key players such as Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China).
Illumina (US) holds a leading position in the NGS market, commanding the largest share. The company offers a comprehensive range of sequencing, genotyping, gene expression, and molecular diagnostic platforms, consumables, and services utilizing SBS technology. Illumina's market dominance is attributed to product launches and strategic collaborations and partnerships. Notable recent products include Urinary Pathogen ID/AMR Panel (UPIP), Viral Surveillance Panel, NovaSeq X Series, NovaSeq 6000 Dx, TruSight Oncology 500 HRD test, Illumina DRAGEN v4.0, and TruSight Oncology (TSO) Comprehensive (EU) test.
Thermo Fisher Scientific (US) occupies the second position in the market, driven by its extensive portfolio of sequencing instruments and consumables. The company focuses on expanding its product portfolio with the introduction of advanced instruments in biotechnology and pharmaceuticals. Thermo Fisher Scientific received FDA approval for the Oncomine Dx Target Test, marking the first NGS-based companion diagnostic kit for therapy selection in patients with RET Mutations/Fusions in thyroid cancers, demonstrating its commitment to innovation and clinical applications.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=546&utm_source=groups&utm_medium=K
The global NGS market is marked by high competitiveness, with key players such as Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China).
Illumina (US) holds a leading position in the NGS market, commanding the largest share. The company offers a comprehensive range of sequencing, genotyping, gene expression, and molecular diagnostic platforms, consumables, and services utilizing SBS technology. Illumina's market dominance is attributed to product launches and strategic collaborations and partnerships. Notable recent products include Urinary Pathogen ID/AMR Panel (UPIP), Viral Surveillance Panel, NovaSeq X Series, NovaSeq 6000 Dx, TruSight Oncology 500 HRD test, Illumina DRAGEN v4.0, and TruSight Oncology (TSO) Comprehensive (EU) test.
Thermo Fisher Scientific (US) occupies the second position in the market, driven by its extensive portfolio of sequencing instruments and consumables. The company focuses on expanding its product portfolio with the introduction of advanced instruments in biotechnology and pharmaceuticals. Thermo Fisher Scientific received FDA approval for the Oncomine Dx Target Test, marking the first NGS-based companion diagnostic kit for therapy selection in patients with RET Mutations/Fusions in thyroid cancers, demonstrating its commitment to innovation and clinical applications.
0 new messages